Log in to search using one of your social media accounts:

 

Efficacy, safety and patient ‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
ObjectivesStudies evaluating the efficacy and safety of the fixed‐dose combination ledipasvir (LDV)/sofosbuvir (SOF) in patients coinfected with HIV‐1 and hepatitis C virus (HCV) have mainly included treatment‐naïve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment‐experienced patients with and without cirrhosis. MethodsWe conducted a multicentre, open‐label, double‐arm, nonrandomized study in patients coinfected with HIV‐1 and HCV genotype 1 with and without cirrhosis, who had good viral suppression on their antiretroviral regimens. All patients we...
Source: HIV Medicine - December 7, 2017 Category: Infectious Diseases Authors: E Rosenthal, C Fougerou ‐Leurent, A Renault, MP Carrieri, F Marcellin, R Garraffo, E Teicher, H Aumaitre, K Lacombe, F Bailly, E Billaud, S Chevaliez, S Dominguez, MA Valantin, J Reynes, A Naqvi, L Cotte, S Metivier, V Leroy, M Dupon, T Allegre, P De Tr Tags: Original Research Source Type: research

Screening for human papillomavirus, cervical cytological abnormalities and associated risk factors in HIV ‐positive and HIV‐negative women in Rwanda
ConclusionsThe currently used quadrivalent vaccine may be insufficient to give satisfactory HPV coverage in Rwanda. HPV Screening may be effective to identify women at risk of developing cervical cancer, particularly if provided to high‐risk patients. (Source: HIV Medicine)
Source: HIV Medicine - December 6, 2017 Category: Infectious Diseases Authors: MF Mukanyangezi, V Sengpiel, O Manzi, G Tobin, S Rulisa, E Bienvenu, D Giglio Tags: Original Research Source Type: research

HbAHP ‐25 attenuates HIV‐1 gp120 mediated inflammation and barrier dysfunction
ConclusionHbAHP‐25 is exceedingly safe to genital epithelial cells and attenuates HIV‐1 gp120‐mediated barrier dysfunction by limiting excessive inflammation. This study provides significant evidences in the favor of HbAHP‐25's potential as a topical anti‐HIV agent. (Source: HIV Medicine)
Source: HIV Medicine - December 6, 2017 Category: Infectious Diseases Authors: T Bashir, KVR Reddy Tags: Original Research Source Type: research

Issue Information
(Source: HIV Medicine)
Source: HIV Medicine - December 4, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Management of drug interactions with direct ‐acting antivirals in Dutch HIV/hepatitis C virus‐coinfected patients: adequate but not perfect
ConclusionsPrescription patterns suggest that physicians are aware of potential DDIs between co‐medication and DAAs, in particular potential DDIs with cART. Greater awareness is needed concerning category 3 interactions between non‐cART co‐medication and DAAs. (Source: HIV Medicine)
Source: HIV Medicine - December 1, 2017 Category: Infectious Diseases Authors: EJ Smolders, C Smit, CTMM Kanter, ASM Dofferhoff, JE Arends, K Brinkman, B Rijnders, M Valk, P Reiss, DM Burger, Tags: Original Research Source Type: research

Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study
ConclusionsA switch to ATV/r or DRV/r may result in more rapid reduction in TC and the TC:HDL‐C ratio in PHIV youth, potentially impacting long‐term cardiovascular disease risk. (Source: HIV Medicine)
Source: HIV Medicine - November 21, 2017 Category: Infectious Diseases Authors: J Jao, W Yu, K Patel, TL Miller, B Karalius, ME Geffner, LA DiMeglio, A Mirza, JS Chen, M Silio, EJ McFarland, RB Van Dyke, D Jacobson, Tags: Original Research Source Type: research

Antiretroviral pill count and clinical outcomes in treatment ‐naïve patients with HIV infection
ConclusionsThis particular single‐tablet regimen is associated with a modest decrease in the risk of AIDS or death relative to multiple‐pill formulations. (Source: HIV Medicine)
Source: HIV Medicine - November 6, 2017 Category: Infectious Diseases Authors: J Young, C Smith, R Teira, P Reiss, I Jarr ín Vera, H Crane, JM Miro, A D'Arminio Monforte, M Saag, R Zangerle, HC Bucher, Tags: Original Research Source Type: research

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV ‐1 positive patients with well‐estimated dates of seroconversion
ConclusionsCD4 count at cART initiation is the most important factor in predicting post‐treatment recovery, but VL provides substantial additional information. If cART is initiated in the first 4 months following seroconversion, recovery of CD4 counts appears to be more rapid. (Source: HIV Medicine)
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: OT Stirrup, AJ Copas, AN Phillips, MJ Gill, RB Geskus, G Touloumi, J Young, HC Bucher, AG Babiker, Tags: Original Research Source Type: research

Pre ‐exposure prophylaxis: awareness, acceptability and risk compensation behaviour among men who have sex with men and the transgender population
ConclusionsWith high acceptability and a low likelihood of risk compensation behaviour, PrEP can be considered as an effective prevention strategy for HIV infection among MSM and TGs in India. (Source: HIV Medicine)
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: CK Uthappa, RR Allam, R Pant, S Pal, M Dinaker, G Oruganti, VV Yeldandi Tags: Original Research Source Type: research

Hospital ‐based routine HIV testing in high‐income countries: a systematic literature review
ConclusionsThere are several barriers to routine HIV testing in EDs and AMUs. Many of these stem from staff fears about offering HIV testing due to the perceived lack of knowledge about HIV. Our systematic review highlights areas which can be targeted to increase coverage of routine HIV testing. (Source: HIV Medicine)
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: A Elgalib, S Fidler, K Sabapathy Tags: Original Research Source Type: research

Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group
ConclusionsThis position statement provides an overview of the key recommendations to optimize the care of WLWH that emerged during the 2016 WAVE workshop. (Source: HIV Medicine)
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: JD Kowalska, K Aebi ‐Popp, M Loutfy, FA Post, MJ Perez‐Elias, M Johnson, F Mulcahy, Tags: Reviews In Antiretroviral Research Source Type: research

Vitamin D and progression of carotid intima ‐media thickness in HIV‐positive Canadians
ObjectivesBased on a growing body of evidence implicating low vitamin D status in the development of cardiovascular disease (CVD), we hypothesized that in Canadian HIV‐positive adults, low 25‐hydroxyvitamin D (25(OH)D) concentration would be associated with increased subclinical vascular disease progression. MethodsWe prospectively studied the relationship between baseline 25(OH)D and subsequent progression of carotid intima‐media thickness (CIMT) between 2002 and 2011, in the Canadian HIV Vascular Study using stored blood specimens. ResultsOf the 128 participants, 89.1% were men, the mean age (standard deviation [SD...
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: H Huff, AT Merchant, E Lonn, E Pullenayegum, F Smaill, M Smieja Tags: Original Research Source Type: research

Food insecurity may lead to incomplete HIV viral suppression and less immune reconstitution among HIV/hepatitis C virus ‐coinfected people
ConclusionsThese findings provide evidence of the negative impact of food insecurity on HIV viral load and CD4 count among HIV/HCV‐coinfected people. (Source: HIV Medicine)
Source: HIV Medicine - November 1, 2017 Category: Infectious Diseases Authors: W Aibibula, J Cox, A ‐M Hamelin, EEM Moodie, AI Naimi, T McLinden, MB Klein, P Brassard, Tags: Original Research Source Type: research

European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16 ‐17 November 2016: a summary
The European AIDS Clinical Society (EACS) organized a second meeting on Standard of Care in Europe on November 16‐17 th, 2016. The aims of the meeting were to discuss and propose actions on three topics, namely: Adherence to guidelines for treatment initiation, treatment monitoring and outcomes, Retention in care and HIV and tuberculosis co‐infection. Several actions need to be implemented in order to further improve quality of care and treatment of HIV in Europe. A common ground for standard of care, based on the EACS Guidelines should be established throughout Europe. EACS plans to interact with policy makers and oth...
Source: HIV Medicine - October 27, 2017 Category: Infectious Diseases Authors: S De Wit, M Battegay, A D'Arminio Monforte, JD Lundgren, C Oprea, A Antinori, S Bhagani, G F ätkenheuer, N Friis‐Moller, H Furrer, C Mussini, Tags: Original Research Source Type: research

A note of thanks to referees for Volume 18, 2017
(Source: HIV Medicine)
Source: HIV Medicine - October 16, 2017 Category: Infectious Diseases Tags: Miscellaneous Source Type: research

Table of Contents
(Source: HIV Medicine)
Source: HIV Medicine - October 16, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Editorial Board
(Source: HIV Medicine)
Source: HIV Medicine - October 16, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir ‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
ConclusionsWe found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups. (Source: HIV Medicine)
Source: HIV Medicine - October 6, 2017 Category: Infectious Diseases Authors: A Cozzi ‐Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich, R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren, A Mocroft, Tags: Original Research Source Type: research

The role of frequent HIV testing in diagnosing HIV in men who have sex with men
ConclusionsThe probability of subsequent HIV diagnosis was greatest in high‐risk MSM who were tested most frequently. Quarterly HIV testing increased the likelihood of identifying undiagnosed HIV infection and should remain a continued recommendation for high‐risk MSM. (Source: HIV Medicine)
Source: HIV Medicine - October 1, 2017 Category: Infectious Diseases Authors: M Furegato, H Mitchell, D Ogaz, S Woodhall, N Connor, G Hughes, A Nardone, H Mohammed Tags: Original Research Source Type: research

Table of Contents
(Source: HIV Medicine)
Source: HIV Medicine - September 4, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Editorial Board
(Source: HIV Medicine)
Source: HIV Medicine - September 4, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

The extent of B ‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people
ConclusionsFLC‐κ, FLC‐λ and IgG levels were higher> 2 years before lymphoma diagnosis, suggesting that B‐cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention. (Source: HIV Medicine)
Source: HIV Medicine - August 31, 2017 Category: Infectious Diseases Authors: L Shepherd, ÁH Borges, R Harvey, M Bower, A Grulich, M Silverberg, J Weber, M Ristola, J‐P Viard, JR Bogner, P Gargalianos‐Kakolyris, C Mussini, K Mansinho, I Yust, D Paduta, D Jilich, T Smiatacz, R Radoi, J Tomazic, P Plomgaard, R Frikke‐Schmidt, Tags: Original Research Source Type: research

Reply to Letter ‘Morning dosing for dolutegravir‐related insomnia and sleep disorders’ by Capetti et al.
(Source: HIV Medicine)
Source: HIV Medicine - August 29, 2017 Category: Infectious Diseases Authors: C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H ‐J Stellbrink, C Wyen Tags: Letter to the Editor Source Type: research

Argon plasma coagulation treatment of anal high ‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study
ConclusionsAPC can be used to treat anal HSILs in HIV‐seropositive MSM, and requires repeated treatment because of a high recurrence rate. As successful treatment of human papillomavirus (HPV) infection or eradication of the anal transitional zone remains impossible, HSIL treatment is challenging and requires long‐term follow‐up. (Source: HIV Medicine)
Source: HIV Medicine - August 23, 2017 Category: Infectious Diseases Authors: A Pokomandy, D Rouleau, R Lalonde, C Beauvais, C Castro, F Coutl ée, Tags: Original Research Source Type: research

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France
Conclusions‘Population’ seems to be more relevant than EDI to define evidence‐based interventions to limit late diagnosis. (Source: HIV Medicine)
Source: HIV Medicine - August 18, 2017 Category: Infectious Diseases Authors: L Cuzin, Y Yazdanpanah, T Huleux, L Cotte, P Pugliese, C Allavena, J Reynes, I Poizot ‐Martin, F Bani‐Sadr, C Delpierre, Tags: Short Communication Source Type: research

HIV ‐infected patients' beliefs about their chronic co‐treatments in comparison with their combined antiretroviral therapy
ObjectivesThanks to the success of combination antiretroviral therapy (cART), HIV‐infected patients can have almost a normal life expectancy. This has resulted in an aging HIV‐infected population with other chronic comorbidities such as cardiovascular diseases, osteoporosis, and depression. Our hypothesis is that patients' perceptions of and attitudes towards their cART, which is perceived as crucial to their survival, differ from their beliefs about their co‐treatments, and this may have an impact on their medication adherence. MethodsWe used the French version of the Beliefs about Medicine Questionnaire (BMQ‐f) t...
Source: HIV Medicine - August 16, 2017 Category: Infectious Diseases Authors: S Kamal, O Bugnon, M Cavassini, MP Schneider Tags: Original Research Source Type: research

Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin?
(Source: HIV Medicine)
Source: HIV Medicine - August 2, 2017 Category: Infectious Diseases Authors: R Rajasingham, DB Meya, DR Boulware Tags: Letter to the Editor Source Type: research

Morning dosing for dolutegravir ‐related insomnia and sleep disorders
(Source: HIV Medicine)
Source: HIV Medicine - August 1, 2017 Category: Infectious Diseases Authors: AF Capetti, S Di Giambenedetto, A Latini, G Sterrantino, I De Benedetto, MV Cossu, A Gori Tags: Letter to the Editor Source Type: research

Table of Contents
(Source: HIV Medicine)
Source: HIV Medicine - August 1, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Editorial Board
(Source: HIV Medicine)
Source: HIV Medicine - August 1, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

HIV incidence in the Estonian population in 2013 determined using the HIV ‐1 limiting antigen avidity assay
ConclusionsThese high HIV incidence estimates in Estonia call for urgent action of renewed targeted public health promotion and HIV testing campaigns. (Source: HIV Medicine)
Source: HIV Medicine - August 1, 2017 Category: Infectious Diseases Authors: P Soodla, R Simmons, K Huik, M Pauskar, E ‐L Jõgeda, H Rajasaar, E Kallaste, M Maimets, R Avi, G Murphy, K Porter, I Lutsar, Tags: Original Research Source Type: research

Discordant rapid HIV tests: lessons from a low ‐resource community
ConclusionsWhen the sample occurrence of discordance between the first and second tests is below 5%, discordant rapid tests in an adult with sexual risk behaviour should trigger strong suspicion of early HIV infection in low HIV prevalence populations. (Source: HIV Medicine)
Source: HIV Medicine - July 31, 2017 Category: Infectious Diseases Authors: AA Adetunji, MA Kuti, RA Audu, SA Muyibi, M Imhansoloeva, OA Mosuro, EA Solanke, OM Akpa, AE Irabor, MMA Ladipo, B Berzins, K Robertson, A Ogunniyi, IF Adewole, BO Taiwo Tags: Short Communication Source Type: research

Severe depression as a neuropsychiatric side effect induced by dolutegravir
(Source: HIV Medicine)
Source: HIV Medicine - July 26, 2017 Category: Infectious Diseases Authors: H Scheper, N Holten, JGFM Hovens, MGJ Boer Tags: Letter to the Editor Source Type: research

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
ObjectivesThe aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004–2013. MethodsMigrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub‐Saharan Africa (SSA), Latin America (LA), Caribbe...
Source: HIV Medicine - July 25, 2017 Category: Infectious Diseases Tags: Original Research Source Type: research

Nucleoside reverse transcriptase inhibitor ‐reducing strategies in HIV treatment: assessing the evidence
Antiretroviral (ARV) therapy, comprising a backbone of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus another ARV, is the recognized standard of care (SOC), which has helped extend life expectancy in people living with HIV. In a quest to reduce lifelong drug exposure and minimize or avoid the toxicity of NRTIs, “NRTI‐reducing” regimens have been investigated. This descriptive review assessing the results of NRTI‐reducing strategies from the largest randomized trials focuses on virological efficacy, resistance, regimen safety (in terms of bone mineral density, renal function, lipids and cent...
Source: HIV Medicine - July 24, 2017 Category: Infectious Diseases Authors: C Orkin, JM Llibre, S Gallien, A Antinori, GMN Behrens, A Carr Tags: Reviews in Antiretroviral Research Source Type: research

Correlates of frailty phenotype and frailty index and their associations with clinical outcomes
ObjectivesFrailty is a predictor of adverse health outcomes and can be measured across the life course, including among people living with HIV. The purpose of this study was to examine two commonly used measures of frailty ‐ the frailty index (FI) and frailty phenotype – to assess common characteristics and to describe associations with multimorbidity, falls, and disability in people aging with HIV. MethodsThis was a cross‐sectional observational study including 482 consecutive HIV‐infected patients (mean age 53.9 ± SD 6.9 years; 75% male) attending the multidisciplinary metabolic clinic at the Universit...
Source: HIV Medicine - July 24, 2017 Category: Infectious Diseases Authors: G Guaraldi, A Malagoli, O Theou, TD Brothers, LMK Wallace, R Torelli, C Mussini, S Sartini, SA Kirkland, K Rockwood Tags: Original Research Source Type: research

The impact of immunoglobulin in acute HIV infection on the HIV reservoir: a randomized controlled trial
ConclusionsAlthough safe, IVIG in AHI did not impact total HIV DNA, immune function or microbial translocation in peripheral blood or gut tissue. (Source: HIV Medicine)
Source: HIV Medicine - July 18, 2017 Category: Infectious Diseases Authors: J Tiraboschi, S Ray, K Patel, A Teague, M Pace, P Phalora, N Robinson, E Hopkins, J Meyerowitz, Y Wang, J Cason, S Kaye, J Sanderson, P Klenerman, S Fidler, J Frater, J Fox Tags: Short communication Source Type: research

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
ObjectivesThe Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor‐5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir‐boosted protease inhibitor (PI/r) component of a two nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] plus PI/r‐based antiretroviral regimen in patients with R5‐tropic virus. Here we report the durability of this finding. MethodsMARCH, an international, multicentre, randomized, 96‐week open‐label switch study, enrolled HIV‐1‐infected adults with R5‐tropic virus who were stable (> 24 weeks) and virologically suppressed [p...
Source: HIV Medicine - July 13, 2017 Category: Infectious Diseases Authors: SL Pett, J Amin, A Horban, J Andrade ‐Villanueva, M Losso, N Porteiro, JS Madero, W Belloso, E Tu, D Silk, A Kelleher, R Harrigan, A Clark, W Sugiura, M Wolff, J Gill, J Gatell, A Clarke, K Ruxrungtham, T Prazuck, R Kaiser, I Woolley, J Alberto Arnaiz, Tags: Short Communication Source Type: research

Table of Contents
(Source: HIV Medicine)
Source: HIV Medicine - July 13, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Editorial Board
(Source: HIV Medicine)
Source: HIV Medicine - July 13, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Insurance status and mortality among patients with AIDS
ConclusionsIn persons with AIDS, compared with those with private insurance, those with public insurance had increased mortality, possibly as a result of a greater burden of noninfectious, age‐related diseases. (Source: HIV Medicine)
Source: HIV Medicine - July 1, 2017 Category: Infectious Diseases Authors: AW Jabs, DA Jabs, ML Van Natta, FJ Palella, CL Meinert, Tags: Original Research Source Type: research

Epidemiology of tuberculosis and HIV coinfections in Singapore, 2000 –2014
Cross‐matching of records between Singapore's tuberculosis and HIV registries showed that 3.3% of individuals with tuberculosis (TB) were coinfected with HIV (2000−2014), the TB incidence among individuals with HIV infection was 1.65 per 100 person‐years, and 53% of coinfections were diagnosed within 1 month of each other. The findings supported joint prevention programmes for early diagnosis and treatment. (Source: HIV Medicine)
Source: HIV Medicine - July 1, 2017 Category: Infectious Diseases Authors: K Nandar, LW Ang, J Tey, L James, KM Kyi Win, CBE Chee, OT Ng, JL Cutter, YT Wang Tags: Short Communication Source Type: research

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV ‐1‐infected subjects with dyslipidaemia
ObjectivesCobicistat seems to have a low rate of adverse events compared with ritonavir. MethodsThis restrospective observational study to evaluated changes in lipid parameters and the percentage of subjects with dyslipidemia in virologically suppressed HIV‐infected patients who were receiving a regimen containing darunavir/ritonavir and were then switched from ritonavir to cobicistat, carried out from December 2015 to May 2016, included 299 HIV‐1‐infected patients who were on stable antiretroviral treatment including darunavir/ritonavir (monotherapy, bitherapy or triple therapy for at least 6 months) and were t...
Source: HIV Medicine - July 1, 2017 Category: Infectious Diseases Authors: P Echeverr ía, A Bonjoch, J Puig, A Ornella, B Clotet, E Negredo Tags: Short Communication Source Type: research

InterPrEP: internet ‐based pre‐exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London – analysis of pharmacokinetics, safety and outcomes
ConclusionsIn a population at high risk of HIV acquisition, who cannot yet access PrEP on the NHS, concentrations of TFV and FTC in generic formulations purchased over the internet were similar to (or slightly higher than) those measured in phase I studies with the original formulation from Gilead (Truvada™), which has demonstrated high levels of protection against HIV infection in previous PrEP clinical trials. (Source: HIV Medicine)
Source: HIV Medicine - June 28, 2017 Category: Infectious Diseases Authors: X Wang, N Nwokolo, R Korologou ‐Linden, A Hill, G Whitlock, I Day‐Weber, MO McClure, M Boffito Tags: Original Research Source Type: research

Importance of the patient ‐physician interaction in assessing acceptability of HIV cure trials
(Source: HIV Medicine)
Source: HIV Medicine - June 20, 2017 Category: Infectious Diseases Authors: C Proti ère, M Préau, P Carrieri, O Lambotte, B Spire, M Suzan‐Monti Tags: Letter to the Editor Source Type: research

HIV testing in persons diagnosed with hepatitis B and C
(Source: HIV Medicine)
Source: HIV Medicine - June 14, 2017 Category: Infectious Diseases Authors: G Ireland, D Ogaz, P Kirwan, S Mandal, V Delpech, N Connor, R Simmons Tags: Letter to the Editor Source Type: research

Prevalence of HIV ‐1 transmitted drug resistance in the incarcerated population
ConclusionsA high prevalence of TDR was identified in the ARV‐naïve incarcerated population. The results of this study indicate an increased prevalence of TDR in a largely unstudied incarcerated population, demonstrating the need for increased monitoring of resistance in HIV‐infected patients world‐wide. (Source: HIV Medicine)
Source: HIV Medicine - June 6, 2017 Category: Infectious Diseases Authors: J Sapozhnikov, JD Young, M Patel, TD Chiampas, P Vaughn, ME Badowski Tags: Original Research Source Type: research

Table of Contents
(Source: HIV Medicine)
Source: HIV Medicine - June 5, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Editorial Board
(Source: HIV Medicine)
Source: HIV Medicine - June 5, 2017 Category: Infectious Diseases Tags: Issue Information Source Type: research

Smoking ‐associated morbidities on computed tomography lung cancer screens in HIV‐infected smokers
(Source: HIV Medicine)
Source: HIV Medicine - May 15, 2017 Category: Infectious Diseases Authors: S Bommart, A Cournil, S Eymard ‐Duvernay, F Raffi, I Bouassida, V Le Moing, J Reynes, A Makinson, Tags: Letter to the Editor Source Type: research